scorecardresearch
Business Today
Subscribe
PMS Today US News India UPSTART Weather BT Shorts NRI Education Election
BT Golf BT Mindrush BT Best Banks
Clear all
Search

COMPANIES

No Data Found

NEWS

No Data Found
Sign in Subscribe
events
Special
  • BT tech today
  • BT 500 wealth creators summit
  • Economic Indicators
News
Markets
Stocks
Suven Pharmaceuticals Ltd

Feedback
Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Ltd (SUVENPHAR) Share Price

  • Sector: Pharmaceuticals (Small Cap)
  • Volume: 454,231
Feb 28, 2025 15:59 IST-
  • NSE
  • BSE
  • Share
    • Whatsapp
    • Twitter
    • Facebook
₹1,214.70
₹56.80 (4.91%)
₹1122.3 Low
Today’s Performance
₹1241.85 High
₹598 Low
52 Week’s Performance
₹1360 High

STOCK ANALYSIS

STOCK PERFORMANCE

  • 1 Day 4.91%
  • 1 Week -0.96%
  • 1 Month 24.55%
  • 3 Months -4.72%
  • 6 Months 14.49%
  • 1 Year 89.03%
  • 3 Years 33.33%
  • 5 Years 48.44%

Company Stories

Macquarie shares 4 CDMO stocks to buy for 19-35% upside Macquarie suggested a target price of Rs 7,400 for Divis Labs, Rs 1,500 for Suven Pharma, Rs 835 for Syngene and Rs 1,000 for Blue Jet Healthcare, suggesting 19-35 per cent upside potential.  Macquarie said Divi's Laboratories and Suven Pharma stand out as product-led CDMOs focusing on advanced technologies such as anti-body drug conjugates (ADCs), peptides and oligonucleotides.

PEER COMPARISON

STOCK SUMMARY

  • Face Value (₹) 1.00
  • Beta 0.45
  • 52-Week Low (₹) 598.00
  • 52-Week High (₹) 1,360.00
  • Price-to-Book (X)* 15.64
  • Dividend Yield (%) 0.00
  • Price-to-Earnings (P/E) (X)* 110.77
  • Earnings Per Share (₹) 10.97
  • Sector Price Earning (X)* 31.64
  • Market Cap (₹ Cr.)* 30,922.01
  • * Vaues as of last close price

COMPETITORS

BT TV

India’s Q3 GDP at 6.2%| What It Means for 'BHARAT' 2:25 India’s Q3 GDP at 6.2%| What It Means for 'BHARAT'
GDP AT 6.2%: WHAT’S NEXT? 1:48 Will India’s GDP Growth Accelerate Beyond 7% This Year? Madan Sabnavis Weighs In
India Q3FY25 GDP Data Explained | Major Highlights & What It Means For You 32:07 India Q3FY25 GDP Data Explained | Major Highlights & What It Means For You
World Bank: India Needs 7.8% Growth To Become High Income Country By 2047 5:40 World Bank: India Needs 7.8% Growth To Become High Income Country By 2047
Sanjay Doshi Of KPMG Tells Us The Effect Of Interest Rate Cuts On The Banking Sector 3:17 Sanjay Doshi Of KPMG Tells Us The Effect Of Interest Rate Cuts On The Banking Sector
View more

FINANCIAL ANALYSIS

Income Statement (₹ Cr.)
Balance Sheet (₹ Cr.)
Cash Flow (₹ Cr.)
Income Statement (₹ Cr.)
Balance Sheet (₹ Cr.)
Cash Flow (₹ Cr.)

RATIO ANALYSIS

Return on Equity (%)
Return on Assets (%)
Price-to-Earnings (P/E) (X)
Price to Book (x)
Return on Capital Employed (%)
Enterprise Value to EBITDA (X)
Net Profit Margin (%)
Gross Profit Margin (%)
EBITDA Margin (%)
Return on Equity (%)
Return on Assets (%)
Price-to-Earnings (P/E) (X)
Price to Book (x)
Return on Capital Employed (%)
Enterprise Value to EBITDA (X)
Net Profit Margin (%)
Gross Profit Margin (%)
EBITDA Margin (%)

SHAREHOLDING PATTERN

Summary (as on 30 sep 2022)

DEALS

  • NSE
  • BSE
Jan 25, 2024 PURCHASE
SOCIETE GENERALE
  • Qty 297913
  • Average Price ₹685.15
Jan 25, 2024 PURCHASE
MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND
  • Qty 176249
  • Average Price ₹685.15
Jan 25, 2024 PURCHASE
MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND
  • Qty 7449
  • Average Price ₹685.15
Jan 25, 2024 Sell
BNP PARIBAS ARBITRAGE
  • Qty 297913
  • Average Price ₹685.15
Jan 25, 2024 Sell
BNP PARIBAS ARBITRAGE
  • Qty 183698
  • Average Price ₹685.15
Oct 17, 2022 PURCHASE
ISHARES CORE MSCI EMERGING MARKETS ETF
  • Qty 503350
  • Average Price ₹406.40
Oct 17, 2022 Sell
ISHARES CORE EMERGING MARKETS MAURITIUS CO
  • Qty 503350
  • Average Price ₹406.40
Oct 17, 2022 Sell
ISHARES INDIA SC MAURITIUS COMPANY
  • Qty 56772
  • Average Price ₹406.40
Oct 17, 2022 PURCHASE
ISHARES MSCI INDIA SMALL-CAP ETF
  • Qty 56772
  • Average Price ₹406.40
Oct 11, 2022 Sell
ISHARES CORE EMERGING MARKETS MAURITIUS CO
  • Qty 244874
  • Average Price ₹419.65
*Single trade that involves transaction of a minimum quantity of 5 lakh shares or a minimum value of ₹ 10 crore.
Aug 16, 2023 Sell
ALPHA ALTERNATIVES MSAR LLP
  • Qty 2091000
  • Average Price ₹520.02
*Involves transaction of at least 0.5% of the listed shares of a company.

FAQ’S

What was Suven Pharmaceuticals Ltd share price previously?
Suven Pharmaceuticals Ltd share price was up by 4.91% from the previous closing price of ₹1,157.90.
Who are peers of Suven Pharmaceuticals Ltd?
The peers of Suven Pharmaceuticals Ltd are Sun Pharmaceuticals Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Zydus Lifesciences Ltd,
Who is/are the promoter/promoters of Suven Pharmaceuticals Ltd?
The promotor/promotors of Suven Pharmaceuticals Ltd are Shweta Jalan, U B Pravin Rao, Venkatanaga Kali Vara Prasad Raju Vetukuri, Pankaj Patwari, Matangi Gowrishankar, Vinod Rao, K G Ananthakrishnan, VIVEK SHARMA, Kundan Kumar Jha, Jaishankar Krishnan, Vinod Padikkal.
What has been 52-week high of Suven Pharmaceuticals Ltd stocks?
The highest price of Suven Pharmaceuticals Ltd stock is ₹1,360.00 in the last 52-week.
What is the share price of Suven Pharmaceuticals Ltd (SUVENPHAR) today on NSE?
As on Feb 28, 2025, Suven Pharmaceuticals Ltd (SUVENPHAR)’s share price on NSE is Rs 1214.7
What is the market cap of Suven Pharmaceuticals Ltd (SUVENPHAR?)
The current market capitalisation of Suven Pharmaceuticals Ltd (SUVENPHAR) is 30,922.01 crores
What is Suven Pharmaceuticals Ltd Share symbol?
The symbol of Suven Pharmaceuticals Ltd is SUVENPHAR.
What is the PE ratio of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The current PE ratio of Suven Pharmaceuticals Ltd (SUVENPHAR) is 110.77.
What is the PB ratio of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The current PB ratio of Suven Pharmaceuticals Ltd (SUVENPHAR) is 15.64.
Today’s High & Low share prices of Suven Pharmaceuticals Ltd (SUVENPHAR) on NSE?
Today, the share price of Suven Pharmaceuticals Ltd (SUVENPHAR) on NSE touched a high of Rs 1241.85 and a low of Rs 1122.3
What price did Suven Pharmaceuticals Ltd (SUVENPHAR) shares open on the NSE today?
On NSE, the share price of Suven Pharmaceuticals Ltd (SUVENPHAR) opened at Rs 1143.9
What is the 52-week high of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The 52-week high price of Suven Pharmaceuticals Ltd (SUVENPHAR) is Rs 1360
What is the 52-week low of Suven Pharmaceuticals Ltd (SUVENPHAR) ?
The 52-week low price of Suven Pharmaceuticals Ltd (SUVENPHAR) is Rs 598

ABOUT SUVEN PHARMA

Suven Pharmaceuticals Ltd, incorporated in the year 2018, has its registered office in 8-2-334 SDE Serene Chambers, 3 Floor Avenue 7 Road No 5, Hyderabad, Telangana, 500034, 91-40-23549414/1142/3311, 91-40-23541152. The main industry in which Suven Pharmaceuticals Ltd operates is Pharmaceuticals - Indian - Bulk Drugs & Formln.

Auditor/Auditors for Suven Pharmaceuticals Ltd is/are Karvy & Co/Walker Chandiok & Co LLP. In the main management, VIVEK SHARMA is chairman and Kundan Kumar Jha is the company secretary for Suven Pharmaceuticals Ltd.

  • SJ Shweta Jalan Non Executive Director
  • UBPR U B Pravin Rao Independent Director
  • VKVPRV Venkatanaga Kali Vara Prasad Raju Vetukuri Managing Director
  • PP Pankaj Patwari Non Executive Director
  • MG Matangi Gowrishankar Independent Director
  • VR Vinod Rao Independent Director
  • KGA K G Ananthakrishnan Independent Director
  • VS VIVEK SHARMA Executive Chairman & Director
  • KKJ Kundan Kumar Jha Company Sec. & Compli. Officer
  • JK Jaishankar Krishnan Additional Director
  • VP Vinod Padikkal Additional Director

Top Stories

Thank you! Your transaction has been completed successfully.
Sorry! Transaction failed. Please try again later.

DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.

DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this website, you agree to the Terms of Service and Privacy Policy.

Advertisement